At the news
? BULLISHIMPACT 6/10 6-K filed Jun 29, 2026 at 06:05 ET
AstraZeneca's Datroway (datopotamab deruxtecan) received a positive CHMP opinion recommending EU approval as 1st-line monotherapy for metastatic triple-negative breast cancer patients ineligible for immunotherapy, based on the TROPION-Breast02 Phase III trial showing a 5.0-month overall survival benefit vs chemotherapy. If approved, Datroway would become the first TROP2-directed ADC in the EU with a demonstrated OS benefit in this frontline setting, expanding its market beyond the existing US approval (May 2026) and HR+/HER2- breast cancer approvals in 40+ countries. The recommendation is a material pipeline catalyst that supports Datroway's peak sales trajectory in a large addressable EU market (estimated ~83,000 annual TNBC diagnoses).
- Datroway recommended for EU approval by CHMP as 1st-line TNBC monotherapy for patients not candidates for PD-1/PD-L1 inhibitor therapy.
- Recommendation based on TROPION-Breast02 Phase III trial showing statistically significant 5.0-month median OS improvement (23.7 vs 18.7 months; HR 0.79; p=0.0291).
- Datroway reduced risk of disease progression or death by 43% (HR 0.57; p<0.0001) vs chemotherapy, with ORR 62.5% vs 29.3%.
- Already approved in the US for this TNBC indication (May 2026) and in HR+/HER2- breast cancer in 40+ countries worldwide.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access